Alzheon Doses First Cohort in Phase 1 Clinical Trial of ALZ-507, a Next-Generation Oral Alzheimer’s Disease Candidate Targeting Amyloid Oligomers and APOE4 Biology
April 18, 2026
No Comments
Alzheon, Inc. today announced that it has successfully dosed the first cohort of healthy volunteers in a Phase 1 clinical trial evaluating ALZ-507, an investigational